Northwestern Mutual Wealth Management Co. Sells 64,703 Shares of Pfizer Inc. $PFE

Key Points

• Northwestern Mutual Wealth Management Co. reduced its Pfizer stake by 11.2% in the second quarter, selling 64,703 shares and retaining 514,459 shares valued at approximately $12.4 million.
• Institutional ownership remains substantial at 68.36%, with several investors—including Handelsbanken Fonder, Russell Investments and Park National—adding to their Pfizer positions.
• Analysts maintain a consensus “Hold” rating with a $28.28 price target. Pfizer recently exceeded quarterly earnings and revenue estimates and declared a $0.43 quarterly dividend, equivalent to a 6.1% annualized yield.

Northwestern Mutual Wealth Management Co. decreased its holdings in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 11.2% in the 2nd quarter, according to its most recent Form 13F filing with the SEC. The firm owned 514,459 shares of the biopharmaceutical company's stock after selling 64,703 shares during the period. Northwestern Mutual Wealth Management Co.'s holdings in Pfizer were worth $12,388,000 as of its most recent SEC filing.

A number of other institutional investors have also added to or reduced their stakes in the business. Handelsbanken Fonder AB increased its position in Pfizer by 10.4% during the 2nd quarter. Handelsbanken Fonder AB now owns 2,462,431 shares of the biopharmaceutical company's stock valued at $59,295,000 after purchasing an additional 232,528 shares during the period. Russell Investments Group Ltd. lifted its position in shares of Pfizer by 15.7% in the 2nd quarter. Russell Investments Group Ltd. now owns 5,482,863 shares of the biopharmaceutical company's stock worth $132,365,000 after purchasing an additional 745,213 shares during the period. Leuthold Group LLC bought a new stake in shares of Pfizer during the 2nd quarter valued at about $4,887,000. North Dakota State Investment Board bought a new stake in shares of Pfizer during the 4th quarter valued at about $5,348,000. Finally, Park National Corp OH increased its position in shares of Pfizer by 332.1% during the second quarter. Park National Corp OH now owns 242,081 shares of the biopharmaceutical company's stock valued at $5,829,000 after buying an additional 186,053 shares during the period. 68.36% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of research analysts have weighed in on the company. Weiss Ratings downgraded Pfizer from a "hold (c)" rating to a "hold (c-)" rating in a report on Monday, August 17th. Wall Street Zen upgraded Pfizer from a "hold" rating to a "buy" rating in a research report on Saturday, August 1st. JPMorgan Chase & Co. reduced their price target on Pfizer from $30.00 to $28.00 and set a "neutral" rating on the stock in a research note on Wednesday, July 8th. Royal Bank Of Canada upgraded Pfizer from an "underperform" rating to a "sector perform" rating and set a $25.00 price objective for the company in a report on Tuesday, June 9th. Finally, Guggenheim lowered their price objective on Pfizer from $35.00 to $31.00 and set a "buy" rating for the company in a research report on Friday, August 7th. One analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, fourteen have assigned a Hold rating and two have issued a Sell rating to the company's stock. According to MarketBeat.com, the stock currently has a consensus rating of "Hold" and a consensus price target of $28.28.

Pfizer Stock Performance

Shares of NYSE PFE opened at $27.97 on Tuesday. The firm's 50-day moving average price is $25.34 and its 200-day moving average price is $26.26. Pfizer Inc. has a 52-week low of $23.58 and a 52-week high of $28.75. The company has a market cap of $159.41 billion, a PE ratio of 36.80 and a beta of 0.34. The company has a quick ratio of 0.96, a current ratio of 1.27 and a debt-to-equity ratio of 0.71.

Pfizer (NYSE:PFE - Get Free Report) last issued its earnings results on Tuesday, August 4th. The biopharmaceutical company reported $0.77 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.68 by $0.09. Pfizer had a net margin of 6.80% and a return on equity of 19.63%. The company had revenue of $15.03 billion for the quarter, compared to analysts' expectations of $14.40 billion. During the same quarter last year, the company posted $0.78 earnings per share. The firm's quarterly revenue was up 2.6% on a year-over-year basis. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. As a group, analysts anticipate that Pfizer Inc. will post 2.98 EPS for the current year.

Pfizer Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 1st. Investors of record on Friday, July 24th will be issued a $0.43 dividend. The ex-dividend date of this dividend is Friday, July 24th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.1%. Pfizer's dividend payout ratio (DPR) is presently 226.32%.

About Pfizer

Pfizer Inc NYSE: PFE is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer's portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source